Literature DB >> 23507216

Prognostication in myelodysplastic syndromes: beyond the International Prognostic Scoring System (IPSS).

Amer M Zeidan, B Douglas Smith, Rami S Komrokji, Steven D Gore.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23507216      PMCID： PMC3768129          DOI： 10.1016/j.amjmed.2012.08.013

Source DB:  PubMed          Journal:  Am J Med        ISSN： 0002-9343            Impact factor:   4.965


× No keyword cloud information.
  8 in total

1.  Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome.

Authors:  Rami S Komrokji; Maria Corrales-Yepez; Najla Al Ali; Mohammad Kharfan-Dabaja; Eric Padron; Teresa Fields; Jeffrey E Lancet; Alan F List
Journal:  Cancer       Date:  2011-09-28       Impact factor: 6.860

Review 2.  Myelodysplastic syndromes: therapy and outlook.

Authors:  Roger M Lyons
Journal:  Am J Med       Date:  2012-07       Impact factor: 4.965

3.  Revised international prognostic scoring system for myelodysplastic syndromes.

Authors:  Peter L Greenberg; Heinz Tuechler; Julie Schanz; Guillermo Sanz; Guillermo Garcia-Manero; Francesc Solé; John M Bennett; David Bowen; Pierre Fenaux; Francois Dreyfus; Hagop Kantarjian; Andrea Kuendgen; Alessandro Levis; Luca Malcovati; Mario Cazzola; Jaroslav Cermak; Christa Fonatsch; Michelle M Le Beau; Marilyn L Slovak; Otto Krieger; Michael Luebbert; Jaroslaw Maciejewski; Silvia M M Magalhaes; Yasushi Miyazaki; Michael Pfeilstöcker; Mikkael Sekeres; Wolfgang R Sperr; Reinhard Stauder; Sudhir Tauro; Peter Valent; Teresa Vallespi; Arjan A van de Loosdrecht; Ulrich Germing; Detlef Haase
Journal:  Blood       Date:  2012-06-27       Impact factor: 22.113

4.  International scoring system for evaluating prognosis in myelodysplastic syndromes.

Authors:  P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

5.  A prognostic score for patients with lower risk myelodysplastic syndrome.

Authors:  G Garcia-Manero; J Shan; S Faderl; J Cortes; F Ravandi; G Borthakur; W G Wierda; S Pierce; E Estey; J Liu; X Huang; H Kantarjian
Journal:  Leukemia       Date:  2007-12-13       Impact factor: 11.528

6.  Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.

Authors:  Hagop Kantarjian; Susan O'Brien; Farhad Ravandi; Jorge Cortes; Jianqin Shan; John M Bennett; Alan List; Pierre Fenaux; Guillermo Sanz; Jean-Pierre Issa; Emil J Freireich; Guillermo Garcia-Manero
Journal:  Cancer       Date:  2008-09-15       Impact factor: 6.860

7.  Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.

Authors:  Rafael Bejar; Kristen E Stevenson; Bennett A Caughey; Omar Abdel-Wahab; David P Steensma; Naomi Galili; Azra Raza; Hagop Kantarjian; Ross L Levine; Donna Neuberg; Guillermo Garcia-Manero; Benjamin L Ebert
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

8.  Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.

Authors:  Luca Malcovati; Ulrich Germing; Andrea Kuendgen; Matteo G Della Porta; Cristiana Pascutto; Rosangela Invernizzi; Aristoteles Giagounidis; Barbara Hildebrandt; Paolo Bernasconi; Sabine Knipp; Corinna Strupp; Mario Lazzarino; Carlo Aul; Mario Cazzola
Journal:  J Clin Oncol       Date:  2007-08-10       Impact factor: 44.544
  8 in total
  13 in total

Review 1.  Iron chelation therapy in myelodysplastic syndromes: where do we stand?

Authors:  Mhairi Mitchell; Steven D Gore; Amer M Zeidan
Journal:  Expert Rev Hematol       Date:  2013-08       Impact factor: 2.929

2.  Getting personal with myelodysplastic syndromes: is now the right time?

Authors:  Nora Chokr; Alexander B Pine; Jan Philipp Bewersdorf; Rory M Shallis; Maximilian Stahl; Amer M Zeidan
Journal:  Expert Rev Hematol       Date:  2019-04-12       Impact factor: 2.929

Review 3.  Current therapy of myelodysplastic syndromes.

Authors:  Amer M Zeidan; Yuliya Linhares; Steven D Gore
Journal:  Blood Rev       Date:  2013-07-27       Impact factor: 8.250

Review 4.  Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?

Authors:  Aziz Nazha; Mikkael A Sekeres; Steven D Gore; Amer M Zeidan
Journal:  Oncologist       Date:  2015-07-20

5.  Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling?

Authors:  Amer M Zeidan; Thomas Prebet; Ehab Saad Aldin; Steven David Gore
Journal:  Expert Rev Hematol       Date:  2014-02-24       Impact factor: 2.929

6.  Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation?

Authors:  Amer M Zeidan; Steven D Gore
Journal:  Expert Rev Hematol       Date:  2013-10-04       Impact factor: 2.929

7.  Lentiviral vector-mediate ATG3 overexpression inhibits growth and promotes apoptosis of human SKM-1 cells.

Authors:  Lin Wang; Jin Song; Jing Zhang; Chen Zhu; Yan Ma; Xiaoping Xu
Journal:  Mol Biol Rep       Date:  2014-01-14       Impact factor: 2.316

Review 8.  Improving Prognostic Modeling in Myelodysplastic Syndromes.

Authors:  Aziz Nazha; Mikkael A Sekeres
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

9.  Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.

Authors:  Dana E Rollison; Kenneth H Shain; Ji-Hyun Lee; Shalaka S Hampras; William Fulp; Kate Fisher; Najla H Al Ali; Eric Padron; Jeffrey Lancet; Qiang Xu; Martha Olesnyckyj; Laurie Kenvin; Robert Knight; William Dalton; Alan List; Rami S Komrokji
Journal:  Cancer Med       Date:  2016-04-20       Impact factor: 4.452

Review 10.  Myelodysplastic syndromes: what do hospitalists need to know?

Authors:  Amer M Zeidan; Bishoy Faltas; B Douglas Smith; Steven Gore
Journal:  J Hosp Med       Date:  2013-05-11       Impact factor: 2.960
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.